Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895823 | 1.00 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EGAAKMT2A | |
| SCHEMBL1306224 | 0.92 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EGAAKMT2A | |
| SCHEMBL1306225 | 0.92 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EGAAKMT2A | |
| SCHEMBL1306170 | 0.89 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAPOLBNPC1 | |
| SCHEMBL1307933 | 0.80 | P2RX3 (0.51) | ALDH1A1SMN1; SMN2KDM4EKMT2AP2RX3 | |
| SCHEMBL1307936 | 0.80 | P2RX3 (0.51) | ALDH1A1SMN1; SMN2KDM4EKMT2AP2RX3 | |
| SCHEMBL2895820 | 0.79 | P2RX3 (0.45) | ALDH1A1SMN1; SMN2KDM4EKMT2AP2RX3 | |
| SCHEMBL3847829 | 0.77 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EPOLBNPC1 | |
| SCHEMBL3847824 | 0.77 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EPOLBNPC1 | |
| SCHEMBL1307250 | 0.77 | LMNA (0.52) | ALDH1A1SMN1; SMN2KDM4EGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2913322-A2 | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same | Korea Research Institute Of Chemical Technology (KR) | 2015-09-02 | — | — | EP | disclosed |
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-18 | — | — | US | disclosed |
| EP-2089354-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Korea Research Institute Of Chemical Technology (KR) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008054154-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069630-A1 | NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC3, HDAC11 | ALDH1A1 673/4885SMN1; SMN2 3845/4885KDM4E 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.